Nature of Operations and Basis of Presentation - Additional Information (Details) - USD ($)															3 Months Ended			6 Months Ended		9 Months Ended	12 Months Ended		37 Months Ended
	Jul. 15, 2023	Jun. 16, 2023	Jun. 15, 2023	May 30, 2023	May 15, 2023	Mar. 21, 2023	Jan. 30, 2023	Mar. 14, 2022	Mar. 04, 2022	Mar. 19, 2021	Jan. 25, 2021	Apr. 30, 2020	Mar. 18, 2020	Nov. 09, 2018	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2023	Jun. 05, 2023	May 12, 2023	Jan. 31, 2023	Dec. 29, 2022	Aug. 19, 2022
Organization Consolidation and Presentation of Financial Statement [Line Items]
Accumulated deficit															$ 165,118,695	$ 140,747,269		$ 165,118,695			$ 140,747,269		$ 165,118,695
Cash and cash equivalents															$ 1,553,416	$ 2,329,218		1,553,416			$ 2,329,218		$ 1,553,416
Net cash used in operating activities																		$ (14,522,079)	$ (12,866,087)
Common stock, par value															$ 0.0001	$ 0.0001		$ 0.0001			$ 0.0001		$ 0.0001
Reimbursement payment										$ 14,000,000.0
Development payments										10,000,000.0
Loss on extinguishment of debt															$ (350,000)			$ (8,541,494)
Threshold equity value as per Nasdaq capital market listing standards																		2,500,000
Threshold market value as per Nasdaq capital market listing standards																		35,000,000
Threshold net income from continuing operations as per Nasdaq capital market listing standards																		$ 500,000
Threshold number of business days for market value of listed securities																				30 days
Threshold number of calendar days to regain compliance																		180 days		180 days
Current liabilities															43,428,348	$ 18,951,700		$ 43,428,348			$ 18,951,700		$ 43,428,348
Deferred collaboration funding, current															181,888	8,412,971		181,888			$ 8,412,971		181,888
Threshold bid price per share for continued listing on nasdaq																								$ 1.00			$ 1.00
Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, net of issuance costs, shares																					772,057
Proceeds from issuance of common stock gross																					$ 1,100,000		4,000,000.0
Collaboration Agreement | Relief Therapeutics Holding AG
Organization Consolidation and Presentation of Financial Statement [Line Items]
Cash payment received										10,000,000.0												$ 10,000,000.0
Repayment of outstanding balance of prior loan and interest										4,000,000.0	$ 4,000,000.0
Reimbursement payment										14,000,000.0	$ 14,000,000.0
Development payments										$ 20,000,000.0
Net profit split ratio based on territory										60.00%	60.00%
Net profit split ratio											60%:40%
Percentage of royalty net sales received										15.00%	15.00%
Milestone payment to be received										$ 6,000,000.0	$ 6,000,000.0
SWK Credit Agreement | Lenders Party and SWK Funding LLC | SOFR
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, periodic payment, principal							$ 600,000									$ 1,300,000		600,000
SWK Credit Agreement | Bridge Loan | Lenders Party and SWK Funding LLC | If ACER-001 Approval does not Occur on or Before September 30, 2022
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument repayment percentage on outstanding principal amount									150.00%
SWK Credit Agreement | Second Term Loan | Lenders Party and SWK Funding LLC
Organization Consolidation and Presentation of Financial Statement [Line Items]
Principal amortization payments			$ 600,000		$ 600,000
Minimum cash balance required by the loan covenants							$ 1,500,000																		$ 3,000,000.0
SWK Credit Agreement | Second Term Loan | Lenders Party and SWK Funding LLC | Repayment Occurs On Or After April 16, 2023 But Prior to May 16, 2023
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument repayment percentage on outstanding principal amount							1.28667%
SWK Credit Agreement | Second Term Loan | Lenders Party and SWK Funding LLC | Repayment Occurs On Or After May 16, 2023 But Prior to June 16, 2023
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument repayment percentage on outstanding principal amount							1.39334%
SWK Credit Agreement | Second Term Loan | Lenders Party and SWK Funding LLC | Repayment Occurs On Or After June 16, 2023
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument repayment percentage on outstanding principal amount							1.50%
SWK Credit Agreement | Second Term Loan | Original Term Loan And Swk Loans
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, principal amount																										$ 7,000,000.0
SWK Credit Agreement | Third Term Loan | Lenders Party and SWK Funding LLC
Organization Consolidation and Presentation of Financial Statement [Line Items]
Principal amortization payments			$ 600,000		$ 600,000
minimum unencumbered liquid assets current requirement															500,000			500,000					500,000
Minimum cash balance required by the loan covenants				$ 1,750,000											1,250,000			1,250,000					1,250,000		$ 3,000,000.0
SWK Credit Agreement | Third Term Loan | Lenders Party and SWK Funding LLC | Subsequent Event
Organization Consolidation and Presentation of Financial Statement [Line Items]
Principal amortization payments	$ 500,000
SWK Credit Agreement | Original Term Loan | Lenders Party and SWK Funding LLC
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, principal amount									$ 6,500,000
Debt instrument, interest rate, increase							3.00%
Origination fees								$ 100,000
Warrant issued to purchase common stock							250,000		150,000																			100,000
Warrant, exercise price							$ 2.39		$ 2.46																			$ 1.51
Loss on extinguishment of debt																		$ (2,700,000)
SWK Credit Agreement | Original Term Loan | Lenders Party and SWK Funding LLC | If ACER-001 Approval does not Occur on or Before December 31, 2022
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, maturity date							Mar. 04, 2024
Debt instrument repayment percentage on outstanding principal amount							150.00%
SWK Credit Agreement | Original Term Loan | Lenders Party and SWK Funding LLC | SOFR
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, interest rate							1.00%
Debt instrument, basis spread on variable rate							11.00%
Marathon Credit Agreement | Term Loan | Lender Party and Marathon
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, principal amount									$ 42,500,000
Debt instrument, interest rate									13.50%
Debt instrument, frequency of periodic payment																		quarterly
Debt instrument, maturity date									Dec. 31, 2028
Termination agreement date									Jan. 30, 2023
Marathon Credit Agreement | Marathon Convertible Notes
Organization Consolidation and Presentation of Financial Statement [Line Items]
Termination agreement date									Jan. 30, 2023
Marathon Convertible Note Purchase Agreement | Marathon Convertible Notes
Organization Consolidation and Presentation of Financial Statement [Line Items]
Loss on extinguishment of debt																		$ (5,000,000.0)
Marathon Convertible Note Purchase Agreement | Marathon Convertible Notes | MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P.
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, principal amount									$ 6,000,000.0
Debt instrument, interest rate									6.50%
Debt instrument, frequency of periodic payment																		quarterly
Conversion price									$ 2.50
Number of business days for repurchase of convertible note							5 days
Increase in Buy-Out percentage							0.2500
Number of business days for payment in full of all senior indebtedness							5 days
Buy-Out percentage				212.50%			200.00%
Securities Purchase Agreement
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, net of issuance costs, shares						2,335,000
Proceeds from issuance of common stock, net of issuance costs						$ 2,300,000
Combined purchase price for one Share and one Common Warrant						$ 0.916
Combined purchase price for one Pre-Funded Warrant and one Common Warrant						0.915
Common stock, par value						$ 0.0001
Proceeds from issuance of common stock gross						$ 2,700,000
Minimum
Organization Consolidation and Presentation of Financial Statement [Line Items]
Threshold number of business days for market value of listed securities																		10 days
Minimum | Marathon Convertible Note Purchase Agreement | Marathon Convertible Notes | MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P.
Organization Consolidation and Presentation of Financial Statement [Line Items]
Gross Proceeds from Issuance or Sale of Equity Debt Hybrid Securities loans or Other Financing							$ 40,000,000.0
Weighted Average | Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, gross sale price per share																					$ 1.42
Maximum
Organization Consolidation and Presentation of Financial Statement [Line Items]
Public float															$ 75,000,000			$ 75,000,000					$ 75,000,000
Common stock bid price per share															$ 1.00			$ 1.00					$ 1.00
Maximum | Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Shares value might be issued under agreement												$ 15,000,000.0
Maximum | Collaboration Agreement | Relief Therapeutics Holding AG
Organization Consolidation and Presentation of Financial Statement [Line Items]
Development payments										$ 20,000,000.0	$ 20,000,000.0
Maximum | SWK Credit Agreement | Lenders Party and SWK Funding LLC | SOFR
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, periodic payment, principal							$ 1,300,000
Pre-Funded Warrants | Securities Purchase Agreement
Organization Consolidation and Presentation of Financial Statement [Line Items]
Warrant issued to purchase common stock						585,306
Warrant, exercise price						$ 0.001
Common Warrants | Securities Purchase Agreement
Organization Consolidation and Presentation of Financial Statement [Line Items]
Warrant issued to purchase common stock						2,920,306
Warrant, exercise price						$ 0.791
Fourth SWK Warrant
Organization Consolidation and Presentation of Financial Statement [Line Items]
Warrant issued to purchase common stock		500,000
Warrant, exercise price		$ 1.00
Warrants expiration date		Jun. 16, 2030
Loss on extinguishment of debt		$ (400,000)
At-the-Market Facility
Organization Consolidation and Presentation of Financial Statement [Line Items]
Remained available under facility															$ 29,000,000.0			$ 29,000,000.0					$ 29,000,000.0
Common stock offering costs															$ 14,000		$ 200,000	$ 200,000	$ 200,000
Issuance of common stock, net of issuance costs, shares															456,886		1,062,547	1,919,140	1,062,547
Proceeds from issuance of common stock, net of issuance costs															$ 300,000		$ 3,100,000	$ 4,300,000	$ 3,100,000
Proceeds from issuance of common stock gross															400,000		$ 3,300,000	$ 4,500,000	$ 3,300,000				$ 21,000,000.0
At-the-Market Facility | Securities Purchase Agreement
Organization Consolidation and Presentation of Financial Statement [Line Items]
Common stock offering costs															$ 14,000
Issuance of common stock, net of issuance costs, shares															456,886
Proceeds from issuance of common stock, net of issuance costs															$ 300,000
Proceeds from issuance of common stock gross															$ 400,000
At-the-Market Facility | Weighted Average
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, gross sale price per share															$ 0.7912		$ 3.0719	$ 2.3290	$ 3.0719
At-the-Market Facility | Weighted Average | Securities Purchase Agreement
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, gross sale price per share															$ 0.7912
At-the-Market Facility | Maximum
Organization Consolidation and Presentation of Financial Statement [Line Items]
Aggregate offering price of common stock													$ 50,000,000.0	$ 50,000,000.0